Principia Biopharma Inc (PRNB) Fundamental Analysis & Valuation

NASDAQ:PRNB

Current stock price

100.05
+0.1 (+0.1%)
At close:
100.02
-0.03 (-0.03%)
After Hours:

This PRNB fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

No Fundamental Analysis report for PRNB not available.

PRNB Fundamentals: All Metrics, Ratios and Statistics

Principia Biopharma Inc

NASDAQ:PRNB (9/25/2020, 8:00:02 PM)

After market: 100.02 -0.03 (-0.03%)

100.05

+0.1 (+0.1%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)N/A
Earnings (Next)N/A
Inst Owners0.02%
Inst Owner Change0%
Ins Owners6.47%
Ins Owner Change0%
Market Cap3.32B
Revenue(TTM)50.00M
Net Income(TTM)-68.91M
Analysts82.8
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 66.45
P/FCF N/A
P/OCF N/A
P/B 9.45
P/tB N/A
EV/EBITDA -41.07
EPS(TTM)-2.41
EYN/A
EPS(NY)-4.82
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS1.51
BVpS10.58
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -17.85%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -148.35%
PM (TTM) -137.82%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.13
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 17.01
Quick Ratio 17.01
Altman-Z 57.63
F-Score1
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-3112.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.71%
EPS Next Y-33.49%
EPS Next 2Y-53.13%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-37.39%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%66.67%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

Principia Biopharma Inc / PRNB Fundamental Analysis FAQ

What is the ChartMill fundamental rating of Principia Biopharma Inc (PRNB) stock?

ChartMill assigns a fundamental rating of 3 / 10 to PRNB.


What is the valuation status for PRNB stock?

ChartMill assigns a valuation rating of 1 / 10 to Principia Biopharma Inc (PRNB). This can be considered as Overvalued.


Can you provide the profitability details for Principia Biopharma Inc?

Principia Biopharma Inc (PRNB) has a profitability rating of 2 / 10.


What is the expected EPS growth for Principia Biopharma Inc (PRNB) stock?

The Earnings per Share (EPS) of Principia Biopharma Inc (PRNB) is expected to decline by -33.49% in the next year.